1. Home
  2. AKBA

as 12-12-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Founded: 2007 Country:
United States
United States
Employees: N/A City: CAMBRIDGE
Market Cap: 336.2M IPO Year: 2014
Target Price: $7.50 AVG Volume (30 days): 1.9M
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.23 EPS Growth: N/A
52 Week Low/High: $0.80 - $2.48 Next Earning Date: 11-07-2024
Revenue: $169,879,000 Revenue Growth: -12.53%
Revenue Growth (this year): -18.98% Revenue Growth (next year): 30.85%

AKBA Daily Stock ML Predictions

Share on Social Networks: